Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First DXM Age Law Passes While Voluntary Restrictions Increase

This article was originally published in The Tan Sheet

Executive Summary

A New York county adopts an ordinance limiting sales of dextromethorphan products to consumers 19 years old and up, while trade groups are looking to a uniform national solution that will curb abuse, maintain consumer access and limit retailer burdens

You may also be interested in...



N.J. Lawmakers To Consider Age Restriction For DXM

The state legislature’s Law and Public Safety Committee in November unanimously passed the bill to require photo identification for purchases of products containing dextromethorphan and impose a fine of up to $750 on employees and retail establishments for violations.

N.J. Lawmakers To Consider Age Restriction For DXM

The state legislature’s Law and Public Safety Committee in November unanimously passed the bill to require photo identification for purchases of products containing dextromethorphan and impose a fine of up to $750 on employees and retail establishments for violations.

Students’ OTC Cough/Cold Drug Abuse Steady, Monitoring Survey Says

Results of the latest national survey of students' illicit drug use show no change in the prevalence of young people abusing OTC cough and cold medicines, and the head researcher says "there is little evidence yet of much improvement" in preventing misuse

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel